Cargando…

Successful naltrexone-bupropion treatment after several treatment failures in a patient with severe monogenic obesity

We describe the therapeutic journey of a 33-year-old patient with early-onset obesity (BMI 56.7 kg/m(2)) and hyperphagia due to a likely pathogenic heterozygous melanocortin-4 receptor (MC4R) gene variant. She was unsuccessfully treated with several intensive lifestyle interventions, gastric bypass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Welling, Mila S., Mohseni, Mostafa, van der Valk, Eline S., van Hagen, Johanna M., Burgerhart, Jan Steven, van Haelst, Mieke M., van Rossum, Elisabeth F.C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982263/ https://www.ncbi.nlm.nih.gov/pubmed/36876127 http://dx.doi.org/10.1016/j.isci.2023.106199

Ejemplares similares

Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
por: Welling, Mila S., et al.
Publicado: (2021)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Naltrexone/Bupropion: Contrave®; Naltrexone SR/Bupropion SR
Publicado: (2012)

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review
por: Dahlberg, Sarah, et al.
Publicado: (2022)

Effect of combined naltrexone and bupropion therapy on the brain’s functional connectivity
por: Wang, Gene-Jack, et al.
Publicado: (2018)

Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia
por: Lyu, Xuechan, et al.
Publicado: (2018)

Resting Energy Expenditure and Body Composition in Children and Adolescents With Genetic, Hypothalamic, Medication-Induced or Multifactorial Severe Obesity
por: Abawi, Ozair, et al.
Publicado: (2022)

RF02 | PSAT110 Resting Energy Expenditure and Body Composition in Children and Adolescents with Genetic, Hypothalamic, Medication-Induced or Multifactorial Severe Obesity
por: Abawi, Ozair, et al.
Publicado: (2022)

A comprehensive diagnostic approach to detect underlying causes of obesity in adults
por: van der Valk, Eline S., et al.
Publicado: (2019)

FRI046 Clinical Phenotyping Of Adults With Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2023)

Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues
por: Wang, G-J, et al.
Publicado: (2014)

The Narrative of a Patient with Leptin Receptor Deficiency: Personalized Medicine for a Rare Genetic Obesity Disorder
por: Welling, Mila S., et al.
Publicado: (2023)

Impact of the COVID-19 Pandemic and Related Lockdown Measures on Lifestyle Behaviors and Well-Being in Children and Adolescents with Severe Obesity
por: Welling, Mila S., et al.
Publicado: (2021)

Bupropion-Induced Severe Leukocytosis
por: Jolly, Taranjeet S, et al.
Publicado: (2020)

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Caixàs, Assumpta, et al.
Publicado: (2014)

Effects of topiramate, bupropion and naltrexone isolated or combined on subcutaneous adipose tissue in obese rats
por: Scudeler, Monica Alhadas, et al.
Publicado: (2022)

The relationship between early weight loss and weight loss maintenance with naltrexone-bupropion therapy
por: le Roux, Carel W., et al.
Publicado: (2022)

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives
por: Tek, Cenk
Publicado: (2016)

Naltrexone/Bupropion extended release‐induced weight loss is independent of nausea in subjects without diabetes
por: Hong, K., et al.
Publicado: (2016)

Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures
por: Siamidi, Angeliki, et al.
Publicado: (2021)

COVID‐19 related anxiety in children and adolescents with severe obesity: A mixed‐methods study
por: Abawi, Ozair, et al.
Publicado: (2020)

Impact of Covid-19 Lockdown Measures on Lifestyle Behavior in Children and Adolescents With Severe Obesity
por: Abawi, Ozair, et al.
Publicado: (2021)

Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date
por: Buehler, Anna M
Publicado: (2015)

Quality of life, binge eating and sexual function in participants treated for obesity with sustained release naltrexone/bupropion
por: Halseth, A., et al.
Publicado: (2018)

Method‐of‐use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity
por: Halseth, Amy, et al.
Publicado: (2016)

Role of Bupropion and Naltrexone in Managing Depression With Polycystic Ovary Syndrome: A Case Report and Literature Review
por: Shah, Kaushal, et al.
Publicado: (2020)

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study
por: McElroy, Susan L., et al.
Publicado: (2013)

Simultaneous determination of naltrexone and bupropion in their co-formulated tablet utilizing green chromatographic approach with application to human urine
por: Abdel-Gawad, Sherif A., et al.
Publicado: (2018)

Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis
por: Pi-Sunyer, Xavier, et al.
Publicado: (2019)

Bariatric Surgery for Monogenic Non-syndromic and Syndromic Obesity Disorders
por: Vos, Niels, et al.
Publicado: (2020)

Low-dose naltrexone as a treatment for chronic fatigue syndrome
por: Bolton, Monica Jane, et al.
Publicado: (2020)

Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial
por: Cho, A-Ra, et al.
Publicado: (2020)

A Randomized, Phase 3 Trial of Naltrexone SR/Bupropion SR on Weight and Obesity-related Risk Factors (COR-II)
por: Apovian, Caroline M, et al.
Publicado: (2013)

Dissolution Assay of Bupropion/Naltrexone Hydrochloride Salts of Bilayer Composition Tablets Following the Development and Validation of a Novel HPLC Method
por: Apostolidi, Anna, et al.
Publicado: (2022)

Stress and Obesity: Are There More Susceptible Individuals?
por: van der Valk, Eline S., et al.
Publicado: (2018)

Dextroamphetamine Treatment for Children With Hypothalamic Obesity
por: van Schaik, Jiska, et al.
Publicado: (2021)

Naltrexone and the Treatment of Alcohol Dependence
por: Volpicelli, Joseph R., et al.
Publicado: (1994)

Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4′-OH-bupropion in vitro
por: Sager, Jennifer E., et al.
Publicado: (2016)

Levels of hormones regulating appetite and energy homeostasis in response to a 1.5-Year combined lifestyle intervention for obesity
por: Kuckuck, Susanne, et al.
Publicado: (2023)

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
por: Hollander, Priscilla, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_q7b7sf5cmdcoqbhgg9hhc5o80s